<DOC>
	<DOCNO>NCT00236574</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety galantamine treatment patient mild cognitive impairment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Galantamine Patients With Mild Cognitive Impairment</brief_title>
	<detailed_description>This international , multicenter , double-blind , randomize , placebo-controlled trial . Following 4 week screening period , patient mild cognitive impairment ( MCI ) , clinically risk development Alzheimer 's disease , randomize treatment either placebo galantamine 24 month either placebo flexible dose galantamine . Efficacy evaluate measure memory cognition ( Alzheimer 's Disease Assessment Scale cognition MCI [ ADAS-cog/MCI ] Clinical Dementia Rating Sum Boxes [ CDR-SB ] ) , global severity dementia ( Clinical Dementia Rating [ CDR ] ) , functionality ( Alzheimer 's Disease Cooperative Study - Activities Daily Living adapt MCI [ ADCS-ADL/MCI ] ) , change serial magnetic resonance imaging ( MRI ) . Safety assess use adverse event report , vital sign , laboratory parameter , physical examination electrocardiogram . The primary study hypothesis galantamine improve memory deficit associate mild cognitive impairment therefore improve stabilize patient 's cognitive ability . A second study hypothesis treatment galantamine slow delay conversion mild cognitive impairment dementia often associate probable Alzheimer 's disease patient . The third study hypothesis treatment well tolerated patient . Galantamine hydrobromide immediate-release tablet ( 4 , 8 , 12 milligram ( mg ) ) take mouth 2 time daily : 4 week 8mg/day , 4 week 16mg/day , increase 24mg/day remainder 24-month trial . Dose may reduce investigator 's discretion 12 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Clinical decline cognitive ability consistent mild cognitive impairment Delayed recall score less equal 10 New York University paragraph recall test Sufficient visual , hear communication capability willingness complete serial standard test cognitive function Have consistent informant accompany schedule visit Be able read , write fully understand language cognitive scale use study Contraindications magnetic resonance imaging , example , presence pacemaker presence metal high risk area Neurodegenerative disorder Parkinson 's disease Cognitive impairment result acute cerebral trauma , hypoxic cerebral damage , vitamin deficiency state , infection meningitis AIDS , primary metastatic cerebral neoplasia Significant endocrine metabolic disease Mental retardation Women pregnant , nursing , lack adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Mild cognitive impairment</keyword>
	<keyword>Galantamine hydrobromide</keyword>
	<keyword>Memory disorder</keyword>
</DOC>